Treating the Transgender Population with Isotretinoin
Speaker: Josh Zeichner, MD
1 CME Credit
Josh Zeichner, MD
Dr. Joshua Zeichner is the Director of Cosmetic and Clinical Research in Dermatology at Mount Sinai Hospital in New York City. He is one of the country’s key opinion leaders in treating acne and is an expert in cosmeceuticals and skin care. He is actively engaged in clinical research, and his work has been published in the top peer-reviewed Dermatology journals. As an educator, Dr. Zeichner trains residents and medical students and regularly lectures to international audiences at the major Dermatology meetings. He is frequently called on by the media for his expert opinion, and he can be found quoted in national magazines and newspapers. Dr. Zeichner is consistently ranked as one of the New York Metro Area’s Top Doctors by Castle Connolly, included as one of New York City Super Doctors published annually in The New York Times Magazine, and was voted by his peers as one of New York Magazine’s Best Doctors in 2020.
What to expect:
- Understand the concerns that may arise in treatment of transgender patients with isotretinoin
- Develop a treatment plan to minimize adverse effects and optimize outcome
- Understand the approach to birth control options with the use of isotretinoin
- Understand the approach to iPledge
Submit your question(s) for the presenter here: